Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Earnings

Bioventus's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 4, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

$142.40M

+2.7% on a year earlier

Non-GAAP earnings of Class A common stock, Q3 FY2026

$0.17

$0.15 a year earlier

Latest guidance

Issued

Nov 2, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Bioventus's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 4, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 26, 2026	Nov 2, 2026after the close	$142.40M	+2.7%	$0.08	$0.17	Release
Q2 FY2026ended Jun 27, 2026	Aug 5, 2026before the open	$153.20M	+3.7%	$0.47	$0.22	Release
Q1 FY2026ended Mar 28, 2026	May 6, 2026before the open	$132.10M	+6.6%	$0.04	$0.15	Release
Q4 FY2025ended Dec 31, 2025	Mar 5, 2026before the open	$157.90M	+2.8%	$0.21	$0.24	Release
Q3 FY2025ended Sep 27, 2025	Nov 4, 2025before the open	$138.70M	-0.2%	$0.05	$0.15	Release
Q2 FY2025ended Jun 28, 2025	Aug 6, 2025before the open	$147.70M	-2.3%	$0.11	$0.21	Release
Q1 FY2025ended Mar 29, 2025	May 6, 2025before the open	$123.90M	-4.3%	-$0.04	$0.08	Release
Q4 FY2024ended Dec 31, 2024	Mar 11, 2025before the open	$153.60M	+13.4%	$0.00	$0.15	Release
Q3 FY2024ended Sep 28, 2024	Nov 5, 2024before the open	$139.00M	+15.1%	-$0.07	$0.06	Release
Q2 FY2024ended Jun 29, 2024	Aug 6, 2024before the open	$151.20M	+10.3%	-$0.37	$0.19	Release
Q1 FY2024ended Mar 30, 2024	May 7, 2024before the open	$129.50M	+8.7%	-$0.07	$0.07	Release
Q4 FY2023ended Dec 31, 2023	Mar 12, 2024before the open	$135.40M	+7.6%	-$0.10	$0.07	Release
Q3 FY2023ended Sep 30, 2023	Nov 7, 2023before the open	$120.80M	-11.9%	-$0.12	$0.05	Release
Q2 FY2023ended Jul 1, 2023	Aug 8, 2023before the open	$137.10M	-2.3%	-$0.06	$0.14	Release
Q1 FY2023ended Apr 1, 2023	May 16, 2023during market hours	$119.10M	+1.5%	-$1.28	-$0.26	Release
Q4 FY2022ended Dec 31, 2022	Mar 31, 2023before the open	$125.80M	-3.5%	-$0.52	-$0.06	Release
Q3 FY2022ended Oct 1, 2022	Nov 8, 2022before the open	$137.10M	+25.9%	$0.03	$0.08	Release
Q2 FY2022ended Jul 2, 2022	Aug 11, 2022before the open	$140.30M	–	-$0.11	$0.10	Release
Q1 FY2022ended Apr 2, 2022	May 10, 2022before the open	$117.30M	–	-$0.19	$0.04	Release
Q4 FY2021ended Dec 31, 2021	Mar 10, 2022before the open	$130.40M	–	-$0.01	$0.26	Release
Q3 FY2021ended Oct 2, 2021	Nov 9, 2021before the open	$108.90M	–	-$0.03	$0.25	Release
Q2 FY2021ended Jul 3, 2021	Jul 29, 2021during market hours	–	–	–	–	Filing
Q1 FY2021ended Apr 3, 2021	May 12, 2021during market hours	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Mar 29, 2021during market hours	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Bioventus's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Net sales	FY2026	$600.00M – $610.00M	$600.00M – $610.00M	Reaffirmed	Aug 5, 2026
Net salesGAAP	FY2026	$600.00M – $610.00M	–	New	Mar 5, 2026
Net SalesGAAP	FY2026	$590.00M – $595.00M	–	New	Nov 2, 2026
Adjusted EPSnon-GAAP	FY2026	$0.75 – $0.79	–	New	Nov 2, 2026
Adjusted EPS*non-GAAP	FY2026	$0.75 – $0.79	$0.75 – $0.79	Reaffirmed	Aug 5, 2026
Adjusted Cash from Operationsnon-GAAP	FY2026	$84.00M – $89.00M	–	New	Nov 2, 2026
Cash from Operations	FY2026	$84.00M – $89.00M	$84.00M – $89.00M	Reaffirmed	Aug 5, 2026
Cash from OperationsGAAP	FY2026	$82.00M – $87.00M	–	New	Mar 5, 2026

Guidance vs results

The last range Bioventus gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Non-GAAP EPS*	$0.64 – $0.68	$0.68Σ4Q	Within range
FY2025	Revenue	$560.00M – $570.00M	$568.20MΣ4Q	Within range

Guidance history

Every forecast Bioventus put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 2, 2026	Adjusted EPS	FY2026	$0.75 – $0.79	New
Nov 2, 2026	Adjusted Cash from Operations	FY2026	$84.00M – $89.00M	New
Nov 2, 2026	Net Sales	FY2026	$590.00M – $595.00M	New
Aug 5, 2026	Adjusted EPS*	FY2026	$0.75 – $0.79	Reaffirmed
Aug 5, 2026	Cash from Operations	FY2026	$84.00M – $89.00M	Reaffirmed
Aug 5, 2026	Net sales	FY2026	$600.00M – $610.00M	Reaffirmed
May 6, 2026	Adjusted EPS*	FY2026	$0.75 – $0.79	Raised
May 6, 2026	Cash from Operations	FY2026	$84.00M – $89.00M	New
May 6, 2026	Net sales	FY2026	$600.00M – $610.00M	New
Mar 5, 2026	Adjusted EPS*	FY2026	$0.73 – $0.77	New
Mar 5, 2026	Cash from Operations	FY2026	$82.00M – $87.00M	New
Mar 5, 2026	Net sales	FY2026	$600.00M – $610.00M	New
Nov 4, 2025	Adjusted EBITDA*	FY2025	$112.00M – $116.00M	New
Nov 4, 2025	Non-GAAP EPS*	FY2025	$0.64 – $0.68	New
Nov 4, 2025	organic growth	FY2025	+6.1% – +8%	New
Nov 4, 2025	Net sales	FY2025	$560.00M – $570.00M	New
Aug 6, 2025	Adjusted EBITDA*	FY2025	$112.00M – $116.00M	Reaffirmed
Aug 6, 2025	Non-GAAP EPS*	FY2025	$0.64 – $0.68	Reaffirmed
Aug 6, 2025	Net sales	FY2025	$560.00M – $570.00M	Reaffirmed
May 6, 2025	Adjusted EBITDA*	FY2025	$112.00M – $116.00M	Reaffirmed
May 6, 2025	Non-GAAP EPS*	FY2025	$0.64 – $0.68	Reaffirmed
May 6, 2025	organic* growth	FY2025	+6.1% – +8%	Reaffirmed
May 6, 2025	Net sales	FY2025	$560.00M – $570.00M	New
Mar 11, 2025	Adjusted EBITDA*	FY2025	$112.00M – $116.00M	New
Mar 11, 2025	Non-GAAP EPS*	FY2025	$0.64 – $0.68	New
Mar 11, 2025	organic* growth	FY2025	+6.1% – +8%	New
Mar 11, 2025	Net sales	FY2025	$560.00M – $570.00M	New
Nov 5, 2024	Adjusted EBITDA*	FY2024	$104.00M – $107.00M	Reaffirmed
Nov 5, 2024	Non-GAAP EPS*	FY2024	$0.40 – $0.42	Raised
Nov 5, 2024	Net sales	FY2024	$562.00M – $567.00M	New
Aug 6, 2024	Adjusted EBITDA*	FY2024	$104.00M – $107.00M	Raised
Aug 6, 2024	Non-GAAP EPS*	FY2024	$0.36 – $0.42	Raised
Aug 6, 2024	Net sales	FY2024	$557.00M – $567.00M	Raised
May 7, 2024	Adjusted EBITDA*	FY2024	$94.00M – $99.00M	Raised
May 7, 2024	Non-GAAP EPS*	FY2024	$0.25 – $0.33	Raised
May 7, 2024	Net sales	FY2024	$535.00M – $550.00M	Raised
Mar 12, 2024	Adjusted EBITDA	FY2024	$89.00M – $94.00M	New
Mar 12, 2024	Non-GAAP EPS	FY2024	$0.12 – $0.20	New
Mar 12, 2024	Net sales	FY2024	$520.00M – $535.00M	New
Nov 7, 2023	Adjusted EBITDA*	FY2023	$84.00M – $87.00M	Raised
Nov 7, 2023	Non-GAAP EPS*	FY2023	-$0.12 – -$0.09	Raised
Nov 7, 2023	Net sales	FY2023	$498.00M – $505.00M	Raised
Aug 8, 2023	Adjusted EBITDA	FY2023	$75.00M – $80.00M	Raised
Aug 8, 2023	Non-GAAP EPS	FY2023	-$0.24 – -$0.20	New
Aug 8, 2023	Net sales	FY2023	$490.00M – $505.00M	New
May 16, 2023	Adjusted EBITDA	FY2023	$68.00M	New
Nov 8, 2022	Adjusted EBITDA	FY2022	$75.00M – $79.00M	Lowered
Nov 8, 2022	Non-GAAP EPS	FY2022	$0.20 – $0.25	Lowered
Nov 8, 2022	Net sales	FY2022	$527.00M – $532.00M	Lowered
Aug 11, 2022	Adjusted EBITDA	FY2022	$94.00M – $104.00M	Lowered
Aug 11, 2022	Non-GAAP EPS	FY2022	$0.47 – $0.57	New
Aug 11, 2022	Net sales	FY2022	$547.50M – $562.50M	Narrowed
May 10, 2022	Adjusted EBITDA	FY2022	$94.00M – $107.00M	Reaffirmed
May 10, 2022	Net sales	FY2022	$545.00M – $565.00M	Reaffirmed
Mar 10, 2022	Adjusted EBITDA	FY2022	$94.00M – $107.00M	New
Mar 10, 2022	Net sales	FY2022	$545.00M – $565.00M	New
Nov 9, 2021	Adjusted EBITDA	FY2021	$77.80M – $82.00M	New
Nov 9, 2021	Net income	FY2021	$1.80M – $3.70M	New
Nov 9, 2021	Non-GAAP net income	FY2021	$72.10M – $75.60M	New
Nov 9, 2021	Net sales	FY2021	$425.00M – $430.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.